Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MF59-adjuvanted H5N6 influenza vaccine
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**MF59-adjuvanted H5N6 influenza vaccine** is an investigational, cell culture-derived, monovalent inactivated subunit vaccine developed by CSL Seqirus for preparedness against avian influenza A/H5N6. Also termed **aH5N6c**, it contains influenza A/H5N6 hemagglutinin antigen formulated with MF59, a squalene-based oil-in-water emulsion adjuvant intended to enhance humoral immune responses. The vaccine has been evaluated in Phase 2 studies in healthy adults, including heterologous H5 prime-boost regimens with related MF59-adjuvanted H5 influenza vaccines. No marketed brand name has been identified.
- Other names
- aH5N6caH-5N6caH 5N6cMF59-adjuvanted cell culture-derived H5N6 influenza vaccineMF-59-adjuvanted cell culture-derived H5N6 influenza vaccineMF 59-adjuvanted cell culture-derived H5N6 influenza vaccineMF59-adjuvanted H5N6 influenza vaccineMF-59-adjuvanted H5N6 influenza vaccineMF 59-adjuvanted H5N6 influenza vaccine
Beyond the preview
Go deeper on MF59-adjuvanted H5N6 influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MF59-adjuvanted H5N6 influenza vaccine.